Welcome to our dedicated page for Profusa SEC filings (Ticker: NVACW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Profusa, Inc. filings document the digital health company’s securities registration activity, material events, and public-company status. Its S-1 and S-1/A registration statements describe offering-related disclosures, security structure, capital structure, risk factors, and the company’s status as an emerging growth company and smaller reporting company.
Profusa’s 8-K reports cover Nasdaq listing compliance matters, material agreements, shareholder voting matters, and other capital-structure or security-structure disclosures. These filings provide the formal record for corporate events affecting the company and its warrant security.
Profusa, Inc. (PFSA) entered into a financing transaction by completing an additional closing under its existing Securities Purchase Agreement with Ascent Partners Fund LLC. Profusa issued Ascent a Senior Secured Convertible Promissory Note with an aggregate principal amount of $329,670.33 for an aggregate purchase price of $300,000.00, reflecting original issue discount. The note is senior, secured and convertible, and it matures on the earlier of September 1, 2027 or the Option Closing Date defined in the note. This creates a new direct financial obligation for Profusa, with potential future equity conversion depending on the note’s terms.
Profusa, Inc. (PFSA) reported that Nasdaq’s Listing Qualifications Department notified the company that, after its recent 1-for-4 reverse stock split, it initially appeared to have fewer than the 500,000 publicly held shares required by Nasdaq Listing Rule 5550(a)(4). After Profusa’s correspondence with Nasdaq on August 21, 2026, Nasdaq determined that Profusa is in compliance with this publicly held shares requirement and has closed its review, with no further action required. Trading of Profusa’s common stock continues on Nasdaq under the symbol PFSA. Profusa states that it will continue monitoring compliance with all Nasdaq continued listing standards and highlights ongoing uncertainty around separate Nasdaq requirements such as the Bid Price, MVLS, and MVPHS rules in its forward-looking statements.
Profusa, Inc. (PFSA) is calling a virtual special stockholders’ meeting on September 18, 2026 to vote on two proposals. The main item would authorize the Board, at its discretion, to implement one or more reverse stock splits of the common stock, at ratios ranging from 1-for-2 to 1-for-12 in total, at any time up to September 18, 2028, without further stockholder approval. As of the August 19, 2026 record date, 605,647 shares of common stock were outstanding.
The Board cites continued listing on Nasdaq’s Capital Market, including compliance with the $1.00 minimum bid price, improved liquidity, and better access to financing (including shelf and equity-line facilities) as key reasons for this authority. The company discloses multiple prior reverse splits in 2026 (including a 1-for-4 split on August 17, 2026) used in efforts to satisfy Nasdaq requirements and notes that failure to maintain listing could severely limit liquidity and capital-raising options. A secondary proposal would permit adjournment of the meeting to solicit more proxies if needed.
Profusa, Inc. (symbol: PFSA) is the issuer of record for a Form 8-K filing submitted to the SEC.
Profusa, Inc. (PFSA) reported progress on its capital structure and its previously signed Option Agreement to acquire G3 Vision Labs, Inc. Debt and liability holders executed $10.7 million of Series A Convertible Exchange Agreements, with $4.57 million converted into Series A Convertible Preferred Stock, and the company states it has sufficient working capital to fund near‑term operations.
Profusa expects PCAOB‑audited 2024 and 2025 financial statements for G3 and its subsidiaries by mid‑September, a key condition to potentially exercising the option to acquire G3 and operate as a public diagnostics company with national CLIA‑certified laboratories and recurring revenues. Profusa also completed a reverse stock split and released its financial results for the quarter ended June 30, 2026.
Profusa, Inc. (PFSA) reports that Chief Financial Officer Fred S. Knechtel, through NorthView Sponsor I LLC, converted a portion of a Convertible Promissory Note into Common Stock on August 12, 2026. The conversion turned $1,292,521 principal of the note into 1,207,964 shares of Common Stock, which became 301,991 shares after a 1‑for‑4 reverse stock split, at an effective post-split conversion price of $4.28 per share (equivalent to $1.07 pre‑split). The note became convertible on May 4, 2026, the Registration Effective Date, under a Note Modification and Conversion Agreement. Following the transaction, 301,991 shares are reported as indirectly held by NorthView Sponsor I LLC, and 147 shares of Common Stock are reported as held directly. The filing states that Mr. Knechtel, as a manager of NorthView Sponsor I LLC, may be deemed to share beneficial ownership of the LLC-held shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
Profusa, Inc. (PFSA) reports that NorthView Sponsor I, LLC converted debt into a substantial equity stake. On August 12, 2026, the Sponsor converted $1,292,521 of principal under a Promissory Note into 1,207,965 common shares at a $1.07 conversion price. After a 1-for-4 reverse stock split, the Sponsor holds 301,991 shares.
Based on 605,726 shares outstanding, the Sponsor beneficially owns approximately 49.9% of Profusa’s common stock. Jack Stover and Fred Knechtel, managers of the Sponsor and officers of Profusa, each report beneficial ownership of about 49.9%, including their indirect interests through the Sponsor.
Profusa, Inc. (PFSA) reported that Chief Executive Officer Jack E. Stover, through NorthView Sponsor I LLC, converted a portion of a Convertible Promissory Note into Common Stock. On August 12, 2026, 1,207,964 shares of Common Stock were issued upon conversion, which became 301,991 shares after a 1-for-4 reverse stock split, at an effective conversion price of $4.28 per share on a post-split basis. The conversion reflected $1,292,521 of note principal converted, and 301,991 indirect shares are reported as held by NorthView Sponsor I LLC, while Stover also holds 73 Common shares directly. Stover may be deemed to share beneficial ownership of the LLC’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Profusa, Inc. (PFSA) reports very strained finances for the quarter ended June 30, 2026. Cash was only $0.7 million with total assets of $1.0 million against total liabilities of $28.2 million, resulting in a stockholders’ deficit of $27.1 million. The company discloses a working capital deficit of about $27.3 million and states that there is substantial doubt about its ability to continue as a going concern within one year.
Profusa recorded a six‑month net loss of $12.2 million and used $5.2 million of cash in operating activities, driven by higher R&D and G&A and large non‑cash financing costs and fair‑value losses on convertible notes. Liquidity currently depends on external financing: the company has a $100 million Equity Line of Credit with Ascent, of which $86.9 million remained available, and remaining borrowing capacity under its Ascent PIPE facility, though future draws are subject to investor discretion and conditions. Profusa also outlines significant Nasdaq listing risk; it has executed multiple reverse stock splits and believes it now meets a $2.5 million stockholders’ equity standard but is awaiting formal Nasdaq confirmation, and warns that failure to comply could lead to delisting and further restrict capital access.
Profusa, Inc. (PFSA) reported that large shareholder HRT FINANCIAL LP, identified as a ten percent owner, executed a sale of common stock. On 2026-08-17, HRT FINANCIAL LP sold 18,395 shares of Profusa common stock at $5.94 per share in a sale described as occurring in the open market or a private transaction. Following this transaction, the reporting holder’s direct ownership in Profusa common stock was reported as 0 shares.